Trial Profile
An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Salbutamol sulfate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Dec 2020 Results published in the European Respiratory Journal
- 21 Feb 2019 Status changed from recruiting to completed.
- 19 Feb 2019 This trial has been completed in Germany (End date: 2019-01-24), according to the European Clinical Trials Database record